SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
April 10, 2012
CELL TECHNOLOGY, INC.
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
|(Commission File Number)
|33 Locke Drive, Marlborough, Massachusetts
|(Address of Principal Executive Offices)
Registrant's Telephone Number, Including
Area Code: (508) 756-1212
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
3.02. Unregistered Sales of Equity Securities.
set forth under Item 8.01 in this current report on Form 8-K is incorporated by reference into this Item 3.02. The New Shares
(as defined below) that we agreed to issue to Black Mountain Equities, Inc. (“BME”) will be issued in reliance upon
the exemption from registration set forth in Section 3(a)(10) of the Securities Act of 1933, as amended.
Item 8.01. Other Events.
April 10, 2012, we entered into a settlement and release agreement (the
“Settlement Agreement”) with BME. The Settlement Agreement relates to
the lawsuit between the parties in the United States District Court for the Southern District of New York, Case No. 11 CIV
7305 regarding certain warrants issued to BME pursuant to a securities purchase agreement dated March 31, 2008.
Pursuant to the Settlement
Agreement, and subject to Court approval, we have agreed, in exchange for dismissal of the pending lawsuit with prejudice and
a mutual release of all claims, to issue to BME an additional 800,000 shares of our common stock (the “New Shares”)
and consent to the delivery to BME of the previously issued 18,000,000 shares of our common stock (the “Escrow Shares”
and together with the New Shares, the “Shares”) (or any proceeds received from the sale of any Escrow Shares) that
were required to be placed in an escrow account pursuant to a preliminary injunction order dated November 9, 2011. The parties
have agreed, in accordance with the terms of the Settlement Agreement, that the Shares are in consideration for any shares of common
stock that were to be issued to BME under the securities purchase agreement and warrants, any claims by BME for damages and the
reimbursement of attorneys fees and costs in connection with the dispute.
Pursuant to the Settlement,
we have filed, along with BME, a joint application for a hearing to determine the fairness of the transactions contemplated by
the Settlement Agreement. If the Court approves the Settlement Agreement, the New Shares and the Escrow Shares (or any proceeds
therefrom) will be delivered to BME on the first business day immediately following such Court approval and the releases will become
effective and the action will be dismissed with prejudice.
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 16, 2012
Advanced Cell Technology, Inc.
By: /s/ Gary H. Rabin
Gary H. Rabin
Chief Financial Officer